Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
121-140 of 3,900 trials

Primary Membranous Nephropathy: Zanubrutinib vs. Tacrolimus

We are studying whether zanubrutinib can reduce protein levels in urine and lead to remission in patients with primary membranous nephropathy compared to tacrolimus. This trial aims to evaluate the safety and effectiveness of both treatments.

Primary Membranous Nephropathy1-2 yearsEfficacy phase (II)Confirmation phase (III)11-15 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteNephrology

HER2-Positive Early Breast Cancer: Inavolisib Study

We are investigating whether adding the drug inavolisib to standard treatments helps patients with HER2-positive, HR-positive, PIK3CA mutant early breast cancer achieve better treatment responses. This study compares the new combination therapy to standard therapy alone.

Breast Cancer3-6 monthsEfficacy phase (II)No PlaceboInvestigational MedicinesOncology

Sedation in Older Critically Ill Patients: Dexmedetomidine vs. Placebo

We are studying whether early sedation with dexmedetomidine improves survival and health outcomes in patients aged 65 and older on ventilators. This trial aims to build on previous findings about sedation in critically ill patients.

Critically Ill PatientsMonitoring phase (IV)Standard MedicinesInternal MedicineOtolaryngologyPsychiatryPulmonology

Acute Myelogenous Leukemia: Siltuximab with Chemotherapy

We are testing a new combination of siltuximab with standard chemotherapy for patients with poor prognosis AML. The goal is to see if this approach improves treatment outcomes.

Acute Myeloblastic Leukemia (AML)>2 yearsSafety phase (I)HematologyOncology

Stroke Prevention: Milvexian Study

We are testing a new oral medication, milvexian, for individuals who have had an acute ischemic stroke or high-risk transient ischemic attack. The study aims to see if it can lower the risk of future strokes and other heart-related issues.

Acute Ischemic Stroke and High-Risk Transient Ischemic Attack>2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteCardiologyInternal Medicine

Pancreatic Cancer: mFOLFIRINOX with Radiation Therapy

We are studying whether adding high-dose radiation therapy to standard chemotherapy helps patients with borderline resectable pancreatic cancer have better surgical outcomes and survival rates.

Pancreatic Cancer3-6 monthsEfficacy phase (II)No PlaceboInvestigational MedicinesGastroenterologyOncology

Diffuse Large B-Cell Lymphoma: Acalabrutinib with R-miniCHOP

We are studying whether adding acalabrutinib to a reduced chemotherapy regimen helps older adults with untreated diffuse large B-cell lymphoma live longer and have better treatment responses. This trial is for those over 60 or 80 years who cannot receive full-dose chemotherapy.

High-Grade B-Cell Lymphoma>2 yearsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesHematologyOncology

Ovarian Cancer Treatment: Carboplatin and Mirvetuximab Soravtansine

We are studying a combination of carboplatin and a new drug, Mirvetuximab soravtansine, for patients with recurrent ovarian cancer that is sensitive to platinum-based chemotherapy. This trial aims to see if this treatment improves response rates in patients with specific tumor characteristics.

Ovarian and Fallopian Tube Cancer>2 yearsEfficacy phase (II)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesOncology

Advanced Solid Tumors: REGN7075 with Cemiplimab

We are studying the safety and effectiveness of a new treatment combining REGN7075 and cemiplimab for patients with advanced cancers. This trial aims to explore how well this combination works and its impact on patients' quality of life.

Malignant Solid TumorSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesPartially RemoteOncology

Heart Failure in Children: Vericiguat Study

We are studying a new medication, vericiguat, to see if it helps improve heart function in children with heart failure. The trial compares its effects to a placebo to ensure safety and effectiveness.

Chronic Systolic Heart FailureEfficacy phase (II)Confirmation phase (III)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteCardiologyPediatrics

Rod Cone Dystrophy: SPVN06 Gene Therapy

We are evaluating the safety and tolerability of a new gene therapy for patients with rod cone dystrophy. This study aims to understand how well the treatment is tolerated in this specific group.

Hereditary Retinal Dystrophy>2 yearsSafety phase (I)Efficacy phase (II)Ophthalmology

Cancer Treatment: Long-term Study of Pembrolizumab

We are evaluating the long-term safety and survival of patients currently on pembrolizumab treatment. This study aims to understand how well the treatment works and its effects over time.

Advanced Cancer>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementOncology

Pembrolizumab for Children with Advanced Melanoma and Solid Tumors

We are studying the safety and effectiveness of pembrolizumab in children with advanced melanoma or certain relapsed solid tumors and lymphoma. This trial aims to understand how well this treatment works and its potential side effects.

Advanced Melanoma and Related CancersSafety phase (I)Efficacy phase (II)No PlaceboStandard MedicinesPartially RemoteOncologyPediatrics

Brexucabtagene Autoleucel for Rare B-cell Malignancies

We are studying a new treatment for adults with relapsed or refractory Richter Transformation of B-cell malignancies. The goal is to see if it improves response rates and overall survival compared to existing options.

Relapsed/Refractory Richter Transformation1-2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesPartially RemoteHematologyOncology

Sodium Bicarbonate for Cardiac Arrest Treatment

We are studying whether sodium bicarbonate can help patients regain heart function during in-hospital cardiac arrest. The trial also looks at its effects on survival and neurological outcomes after 30 days.

In-Hospital Cardiac Arrest1-2 yearsMonitoring phase (IV)Standard MedicinesCardiology

Colorectal Cancer: UNICORN Study on Targeted Preoperative Treatments

We are studying short-course targeted treatments for patients with resectable colorectal cancer to see if they improve treatment response and quality of life. This trial aims to understand the safety and effectiveness of these treatments before surgery.

Colorectal Adenocarcinoma1-2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesOncology

Preventing Second Cancers: Dostarlimab Study

We are studying whether dostarlimab can help prevent second primary cancers in patients who have been cured of their first cancer. This trial will also look at the safety of the treatment.

Cancer Survivor at Risk for Second Cancer≤3 monthsEfficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesOncology

Multiple Sclerosis: Ozanimod vs. Fingolimod

We are studying whether the new medication ozanimod is more effective and safe than fingolimod for children and adolescents with relapsing remitting multiple sclerosis. This trial will also assess how the body handles ozanimod.

Relapsing-Remitting Multiple SclerosisConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesNeurology

Rituximab for Progressive Interstitial Lung Disease

We are studying whether rituximab can improve lung function in patients with progressive interstitial lung disease. This trial compares its effects to a placebo to assess safety and quality of life.

Interstitial Lung Disease>2 yearsEfficacy phase (II)Confirmation phase (III)≤5 visitsStandard MedicinesInternal MedicinePulmonology

Severe Eosinophilic Asthma: Benralizumab for Kids

We are studying whether benralizumab can help children with severe eosinophilic asthma by reducing asthma attacks and improving their symptoms. This trial will also look at the safety of the medication.

Severe Eosinophilic Asthma>2 yearsConfirmation phase (III)Post-Trial Drug AccessInvestigational MedicinesPartially RemoteAllergologyPulmonology